InvestorsHub Logo
Followers 481
Posts 60466
Boards Moderated 18
Alias Born 09/20/2001

Re: maumar post# 5129

Wednesday, 02/01/2017 12:09:54 PM

Wednesday, February 01, 2017 12:09:54 PM

Post# of 8545
So this is an urgent matter for Roche:




The company: Roche
Estimated worldwide sales 2012: $6.08 billion

Herceptin has long been the dominant breast cancer drug on the market. And Roche ($RHHBY) has been steadily building sales around the world. In a recent report, Decision Resources noted that overall the entire category for breast cancer therapies is likely to rise significantly for another 6 years. And with patent expiration coming in 2014 for Europe and 2018 or 2019 for the U.S.--which will open the way for biosimilars now in development--Roche has a limited window open to capitalize on the opportunity.



http://www.fiercepharma.com/special-report/herceptin-1




In Peace, In War

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News